Viteyes AREDS 2 (3 Month Supply)

Viteyes AREDS 2 Formula is based on the findings of the AREDS 2 study. Completed in 2013, AREDS 2 was a 5-year follow-up study by the National Eye Institute (NEI) of the original AREDS study. AREDS 2 resulted in the NEI's recommendation to revise the original AREDS formula to help further slow the progression of vision loss from AMD.* Viteyes AREDS 2 contains the following formula: Vitamin C 500 mg, Vitamin E 400 IU, Zinc 25 mg, Copper 2 mg, Lutein 10 mg, Zeaxanthin 2 mg. AREDS 2 analyzed the original AREDS formula with and without beta-carotene, due to the concern of increased risk of lung cancer for smokers and former smokers. The AREDS 2 study also researched adding lutein and zeaxanthin. AREDS 2 Results: Omit Beta-Carotene, Add Lutein & Zeaxanthin: AREDS 2 participants who took lutein and zeaxanthin and no beta-carotene reduced their risk of developing advanced stages of AMD by 18% compared to those in AREDS 2 who took the original AREDS supplement with beta-carotene. As a result, the NEI's AREDS 2 suggests modifying the AREDS formula by omitting beta-carotene and adding lutein and zeaxanthin. Zinc Levels: In the original AREDS study, the dose for zinc was set high (80 mg) because a previous small trial had found that high-dose zinc was beneficial for AMD. However, some nutritionists were concerned the dose was too high.* The AREDS 2 study tested zinc at 80 mg and 25 mg. The results showed that when lowering zinc there was "no statistically significant effect on progression to advanced AMD."** (*NEI website 2013. AREDS 2 Media Q&A http://www.nei.nih.gov/areds2/MediaQandA.asp **AREDS2 Research Group. "Lutein/Zeaxanthin and Omega-3 Fatty Acids for Age-Related Macular Degeneration. The Age-Related Eye Disease Study 2 (AREDS2) Controlled Randomized Clinical Trial." JAMA, published online May 5, 2013.) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.